Engage key stakeholders with enhanced market access strategies and innovative pricing agreements

Hear from world class speakers:

eyeforpharma's Oncology Market Access Europe Summit brings together a top selection of Pharma specialists and experienced professionals to share their knowledge, their views and give you insight into how they are dealing with the challenges and opportunities presented by the massive growth of oncology treatment, alongside the changing pharma landscape.

Come to the conference and you will gain insights into:

• Market Access: Enhance your market entry strategies and demonstrate added value to your key stakeholders
• Pricing and Reimbursement: Learn from case studies on innovative contracts concerning high-value treatments
• Oncology Marketing Strategies: Evolve your oncology marketing plan for a more targeted approach
• Effective Stakeholder Communication: Hear from the HTA, payers’ and patients’ perspective to improve collaboration at all stages

Session one will focus on the current and future challenges in the oncology market access landscape. Peter Boyle, President of the International Prevention Research Institute will provide insight on the impact of the cancer burden on low-income countries and the challenge that global disparities pose for the future.

Session two is a special session on marketing innovation in oncology. Hear from Karol Sikora, Cancer Partners UK, present on biomarkers and companion diagnostics as oncology marketing tools. Uday Bose, European Head of Oncology, Eisai will examine how to differentiate your oncology product in a competitive market.

Session three’s will focus on demonstrating added value when bringing new oncology drugs to market. Hear about innovative pricing and market access schemes in practice from Anant Murthy, Head of Market Access Europe, Celgene.

Session four will provide insights from all the key stakeholders involved in pricing and reimbursement. Claudia Wild, Director of the Ludwig Boltzman Institute for HTA, Austria will present on how to utilise horizon scanning programmes to inform reimbursement decision-makers on the benefits and risks of pipeline drugs. Alain Dostie, Business Unit Head Oncology Czech & Slovak Republic, Novartis will provide insight on approaches to pricing and market access of oncology drugs in Eastern Europe.

See the full speaker line-up here

Also hear from our leading sponsors and educational partners in the oncology market place: Kantar Health and idis:

Anne-Pierre Pickaert, will be outlining the marketing authorization procedures applying to cancer drugs and the impact of EU law on cancer care provision and coverage.

Mark Corbett, will be leading a practical discussion on how to optimise global market access for innovative drugs through use of early access programmes.

Networking opportunities

Over 100 leaders and innovators in oncology market access will be in the same room and eager to exchange ideas and share experiences with you. The design of the event maximises networking time with over 12 hours applied over the 2 days. The highlight is the networking party after the close of business on day one of the summit, April 13th.